The European Commission granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adult patients with relapsed or refractory follicular lymphoma. The approval is based on results from the pivotal phase III EPCORE FL-1 trial that evaluated fixed-duration Tepkinly + R2 compared to standard of care R2.
Prediction market exchanges have allowed the public to bet on the ousting of Nicolás Maduro, the outcome of the Spain v. Argentina World Cup final, and whether Trump will use the word “hippopotamus” in the month of July.
